胆汁淤积
生物标志物
医学
无症状的
生物信息学
内科学
生物
生物化学
作者
Alanah Pieters,Eva Gijbels,Bruno Cogliati,Pieter Annaert,Lindsey Devisscher,Mathieu Vinken
出处
期刊:Biomarkers in Medicine
[Future Medicine]
日期:2021-03-12
卷期号:15 (6): 437-454
被引量:15
标识
DOI:10.2217/bmm-2020-0691
摘要
Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The ‘omics’ era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks.
科研通智能强力驱动
Strongly Powered by AbleSci AI